ARTICLE
7 June 2024

FTC Theories Of Harm After Anesthesia Co. Ruling

M
Mintz

Contributor

Mintz is a litigation powerhouse and business accelerator serving leaders in life sciences, private equity, sustainable energy, and technology. The world’s most innovative companies trust Mintz to provide expert advice, protect and monetize their IP, negotiate deals, source financing, and solve complex legal challenges. The firm has over 600 attorneys across offices in Boston, Los Angeles, Miami, New York, Washington, DC, San Francisco, San Diego, and Toronto.
They also highlighted the broader implications for private equity transactions in health care under the new FTC merger guidelines.
United States Texas Antitrust/Competition Law

Antitrust Co-chairs Bruce Sokler and Joe Miller, along with Associate Payton Thornton co-authored an article in Law360 discussing key takeaways from a Texas judge's decision to dismiss a private equity firm from the Federal Trade Commission's lawsuits against the firm and US Anesthesia Partners Inc. They also highlighted the broader implications for private equity transactions in health care under the new FTC merger guidelines.

The authors wrote, "Dismissal of the private equity sponsor from the suit is not fatal to the underlying theme of the FTC's case, which will proceed against the anesthesia group defendant and could potentially advance the antitrust agencies' ability to unwind transactions that cumulatively increase a firm's power in a given market."

SOURCE

Law360

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More